Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Luminal B/HER2-negative Breast Cancer
Interventions: DRUG: Dalpiciclib combined with aromatase inhibitors
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: GeneCast Biotechnology Co., Ltd.